| |
| |
|
| Insider
Information: |
Schroeder Theodore R |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
22,996 |
|
|
Indirect Shares
|
117,489 |
|
|
| Direct
Value |
$380,610 |
|
|
|
Indirect Value
|
$46,267 |
|
|
| Total
Shares |
140,485 |
|
|
| Total
Value |
$426,877 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -100.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Cadence Pharmaceuticals Inc |
CADX |
President, CEO, Director |
2014-03-19 |
0 |
2014-03-19 |
0 |
Premium* |
|
|
Hyperion Therapeutics Inc |
HPTX |
Director |
2015-05-07 |
0 |
2014-08-13 |
0 |
Premium* |
|
|
Collegium Pharmaceutical, Inc |
COLL |
Director |
2020-05-20 |
11,007 |
2018-05-24 |
0 |
Premium* |
|
|
Nabriva Therapeutics AG |
NBRV |
Director |
2023-01-29 |
11,989 |
2019-08-27 |
117,489 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
90 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CADX |
Cadence Pharmaceuticals I... |
President, CEOOfficer |
• – – |
2006-10-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
500,000 |
|
- |
|
| CADX |
Cadence Pharmaceuticals I... |
President, CEO |
• • – |
2010-11-11 |
5 |
GD |
$0.00 |
$0 |
I/I |
19,500 |
291,500 |
0 |
- |
|
| CADX |
Cadence Pharmaceuticals I... |
President, CEO |
• • – |
2011-11-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
0 |
- |
|
| HPTX |
Hyperion Therapeutics Inc |
Director |
– • – |
2014-08-13 |
4 |
A |
$0.00 |
$0 |
D/D |
3,700 |
3,700 |
0 |
- |
|
| COLL |
Collegium Pharmaceutical,... |
Director |
– • – |
2018-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,253 |
2,253 |
0 |
- |
|
| COLL |
Collegium Pharmaceutical,... |
Director |
– • – |
2019-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,707 |
6,960 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2019-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
6,748 |
67,489 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2020-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
343,800 |
646,560 |
0 |
- |
|
| COLL |
Collegium Pharmaceutical,... |
Director |
– • – |
2020-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,047 |
11,007 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2021-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
117,500 |
182,018 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-08-31 |
4 |
D |
$0.16 |
$18 |
D/D |
(107) |
312,202 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-09-06 |
4 |
D |
$0.16 |
$35 |
D/D |
(225) |
311,977 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-06-30 |
4 |
D |
$0.18 |
$19 |
D/D |
(107) |
312,866 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-07-06 |
4 |
D |
$0.18 |
$41 |
D/D |
(225) |
312,641 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-07-31 |
4 |
D |
$0.18 |
$19 |
D/D |
(107) |
312,534 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-08-06 |
4 |
D |
$0.18 |
$42 |
D/D |
(225) |
312,309 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-06-06 |
4 |
D |
$0.20 |
$45 |
D/D |
(225) |
312,973 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-05-31 |
4 |
D |
$0.21 |
$22 |
D/D |
(107) |
313,198 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-05-06 |
4 |
D |
$0.26 |
$59 |
D/D |
(225) |
313,305 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-04-30 |
4 |
D |
$0.31 |
$33 |
D/D |
(107) |
313,530 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-04-06 |
4 |
D |
$0.41 |
$90 |
D/D |
(219) |
313,637 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-03-31 |
4 |
D |
$0.42 |
$44 |
D/D |
(104) |
313,856 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2020-11-30 |
4 |
D |
$0.43 |
$517 |
D/D |
(1,211) |
646,396 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-03-06 |
4 |
D |
$0.43 |
$113 |
D/D |
(263) |
313,960 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-01-29 |
4 |
D |
$0.45 |
$4,845 |
D/D |
(10,766) |
314,736 |
0 |
- |
|
90 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
